5-甲酰基-2-呋喃基苯甲酸乙酯 | 19247-87-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 5-甲酰基-2-呋喃基苯甲酸乙酯
• 中文别名: 4-(5-甲酰基-2-呋喃基)苯甲酸乙酯
• 英文名称: 5-(4-Ethoxycarbonylphenyl)-fural
• 英文别名: Ethyl 4-(5-formyl-2-furyl)benzoate；ethyl 4-(5-formylfuran-2-yl)benzoate
• CAS: 19247-87-1
• 化学式: C₁₄H₁₂O₄
• mdl: MFCD00778531
• 分子量: 244.247
• InChiKey: UWLKFGFYBKJASW-UHFFFAOYSA-N

物化性质

• 熔点：
  113-115 °C
• 沸点：
  404.7±40.0 °C(Predicted)
• 密度：
  1.199±0.06 g/cm3(Predicted)
• 稳定性/保质期：
  在常温常压下稳定，应避免与氧化物接触。

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  56.5
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2932190090
• 储存条件：
  常温下应密闭避光保存，并保持通风干燥。

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 2-[4-(4-Piperidinyloxy)Phenyl]Acetamide
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 4), H302
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xn Harmful R22
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Warning
Hazard statement(s)
H302 Harmful if swallowed.
Precautionary statement(s) none
Supplemental Hazard none
Statements
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

---

SECTION 3: Composition/information on ingredients
Substances
Molecular weight : 244,25 g/mol
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
2-[4-(4-Piperidinyloxy)Phenyl]Acetamide
Acute Tox. 4; H302 <= 100 %
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
2-[4-(4-Piperidinyloxy)Phenyl]Acetamide
Xn, R22 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
No data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Nature of decomposition products not known.
Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.
Further information
No data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Storage class (TRGS 510): Non Combustible Solids
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour No data available
c) Odour Threshold No data available
d) pH No data available
e) Melting point/freezing No data available
point
f) Initial boiling point and No data available
boiling range
g) Flash point No data available
h) Evaporation rate No data available
i) Flammability (solid, gas) No data available
j) Upper/lower No data available
flammability or
explosive limits
k) Vapour pressure No data available
l) Vapour density No data available
m) Relative density No data available
n) Water solubility No data available
o) Partition coefficient: n- No data available
octanol/water
p) Auto-ignition No data available
temperature
q) Decomposition No data available
temperature
r) Viscosity No data available
s) Explosive properties No data available
t) Oxidizing properties No data available
Other safety information
No data available

---

SECTION 10: Stability and reactivity
Reactivity
No data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
No data available
Conditions to avoid
No data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
No data available
Persistence and degradability
No data available
Bioaccumulative potential
No data available
Mobility in soil
No data available
Results of PBT and vPvB assessment
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Other adverse effects
No data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
No data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
No data available
Chemical Safety Assessment
For this product a chemical safety assessment was not carried out

---

SECTION 16: Other information
Full text of H-Statements referred to under sections 2 and 3.
Acute Tox. Acute toxicity
H302 Harmful if swallowed.
Full text of R-phrases referred to under sections 2 and 3
Xn Harmful
R22 Harmful if swallowed.
Further information
Copyright 2014 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

反应信息

• 作为反应物：
  描述：

  5-甲酰基-2-呋喃基苯甲酸乙酯 在 哌啶 、 盐酸羟胺 作用下， 以 乙醇 为溶剂， 反应 0.5h， 以83%的产率得到5-(4'-ethoxycarbonylphenyl)furan-2-carbaldehyde oxime
  参考文献：
  名称：

  Synthesis of Arylfurfural Oximes and Their Biological Evaluation

  摘要：

  通过元素分析和光谱技术（傅立叶变换红外光谱、1H NMR、13C NMR 和质谱），制备并表征了各种芳基糠醛肟。对合成的化合物进行了抗氧化、酪氨酸酶和化学胰蛋白酶活性测试。

  DOI：

  10.14233/ajchem.2016.19624
• 作为产物：
  描述：

  在 盐酸 作用下， 生成 5-甲酰基-2-呋喃基苯甲酸乙酯
  参考文献：
  名称：

  Synthesis of 5-Pyridyl-2-furaldehydes via Palladium-Catalyzed Cross-Coupling with Triorganozincates

  摘要：

  [GRAPHICS]-Pyridyl- and 5-aryl-2-furaidehydes are prepared from furaldehyde diethyl acetal in a four-step, one-pot procedure: (1) deprotonation; (2) U to Zn transmetalation; (3) Pd-medlated cross-coupling; (4) aldehyde deprotection. Triorganozincate 7 was found to transfer all three groups in the Pd-catalyzed cross-coupling reaction with haloaromatics.

  DOI：

  10.1021/ol0170612

文献信息

• Discovery of novel inhibitors of human phosphoglycerate dehydrogenase by activity-directed combinatorial chemical synthesis strategy
  作者：Xia Zhou、Yuping Tan、Kun Gou、Lei Tao、Yuan Luo、Yue Zhou、Zeping Zuo、Qingxiang Sun、Youfu Luo、Yinglan Zhao

  DOI：10.1016/j.bioorg.2021.105159

  日期：2021.10

  adopted activity-directed combinatorial chemical synthesis strategy to optimize this hit compound. Compound b36 was found to be the noncompetitive and the most promising one with IC50 values of 5.96 ± 0.61 μM against PHGDH. Compound b36 inhibited the proliferation of human breast cancer and ovarian cancer cells, reduced intracellular serine synthesis, damaged DNA synthesis, and induced cell cycle arrest

  丝氨酸是从头合成嘌呤和脱氧胸苷所必需的一碳单元的来源，在癌细胞的生长中起着至关重要的作用。磷酸甘油酸脱氢酶 (PHGDH) 催化丝氨酸从头生物合成中的第一个限速步骤，已成为治疗癌症的有希望的靶点。在这里，我们从基于酶促测定的内部小分子库的筛选中确定了H-G6作为潜在的 PHGDH 抑制剂。我们采用了活性导向的组合化学合成策略来优化这种命中化合物。发现化合物b36是非竞争性和最有前途的化合物，其对 PHGDH 的IC 50值为 5.96 ± 0.61 μM。化合物b36抑制人乳腺癌和卵巢癌细胞的增殖，减少细胞内丝氨酸合成，破坏DNA合成，并诱导细胞周期停滞。总的来说，我们的结果表明b36是一种新型的 PHGDH 抑制剂，它可能是一种有前景的调节丝氨酸合成途径的调节剂，并且可能是一种潜在的抗癌先导物，值得进一步探索。
• Highly Functionalized Biaryls via Suzuki-Miyaura Cross-Coupling Catalyzed by Pd@MOF under Batch and Continuous Flow Regimes
  作者：Vlad Pascanu、Peter R. Hansen、Antonio Bermejo Gómez、Carles Ayats、Ana E. Platero-Prats、Magnus J. Johansson、Miquel À. Pericàs、Belén Martín-Matute

  DOI：10.1002/cssc.201402858

  日期：2015.1

  currently existing commercial procedures. Most importantly, Pd@MIL‐101‐NH2 was packed in a micro‐flow reactor, which represents the first report of metallic nanoparticles supported on MOFs employed in flow chemistry for catalytic applications. A small library of 11 isolated compounds was created in a continuous experiment without replacing the catalyst, demonstrating the potential of the catalyst for large‐scale

  通过在功能化介孔MOF（8 wt％Pd @ MIL-101（Cr）-NH 2）中负载的Pd纳米粒子催化的Suzuki-Miyaura交叉偶联反应，成功合成了多种多样的40多种高度官能化的联芳基。尽管存在各种官能团和/或几个杂原子，但可以在迄今报道的某些最温和的条件下实现这一目标，并且可以保持对金属物种浸出的强有力控制。一些目标分子是药物合成中的重要中间体，我们清楚地举例说明了该催化系统的多功能性，与当前现有的商业程序相比，该催化系统的收率更高。最重要的是，Pd @ MIL-101-NH 2将其装在微流反应器中，这代表了在流化学中用于催化应用的MOF上负载的金属纳米颗粒的首次报道。在不替换催化剂的情况下，通过连续实验创建了一个11个分离的化合物的小型文库，证明了该催化剂在大规模应用中的潜力。
• 作为阿片样物质受体的拮抗剂或反向激动剂的 新型化合物
  申请人：史密丝克莱恩比彻姆公司

  公开号：CN102516115B

  公开（公告）日：2016-05-11

  本发明涉及作为阿片样物质受体的拮抗剂或反向激动剂的新型化合物。本发明提供作为一种或多种阿片样物质受体上的拮抗剂或反向激动剂的新型化合物、含有该新化合物的药物组合物及它们的制备方法。
• METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS
  申请人：IGNAR DIANE MICHELE

  公开号：US20100113512A1

  公开（公告）日：2010-05-06

  A method of treatment using pharmaceutical compositions containing novel antagonists or inverse agonists at opioid receptors for the treatment of binge eating disorder, anorexia nervosa, bulimia nervosa, excess drug or alcohol use, or eating disorder not otherwise specified.

  使用含有新型阿片受体拮抗剂或反向激动剂的药物组合物治疗暴食症、厌食症、暴食症、过度药物或酒精使用或其他未明确指定的进食障碍的治疗方法。
• NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS
  申请人：Cowan David John

  公开号：US20110124559A1

  公开（公告）日：2011-05-26

  Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.

  小说化合物，它们是阿片受体的拮抗剂或逆向激动剂，含有它们的药物组合物，以及它们的制备方法。